Candel Therapeutics (CADL) to Release Earnings on Tuesday

Key Points

• Candel Therapeutics (CADL) will report Q1 2026 results before the market opens on Tuesday, May 12, with analysts modeling EPS of -$0.2958; the company missed the prior quarter (reported -$0.54 vs. consensus -$0.24).
• Analyst coverage is mixed (six Buys, one Hold, two Sells) and the consensus rating is "Hold" with an average price target of $18, well above the current share price (~$7.80).
• Director Paul B. Manning bought 550,458 shares at an average of $5.45 (≈$3.0M), increasing his stake by 24.9%; insiders now own about 16.6% of the company.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Candel Therapeutics to post earnings of ($0.2958) per share for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.30). On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Candel Therapeutics Price Performance

NASDAQ CADL traded up $0.27 on Tuesday, reaching $7.80. The company had a trading volume of 1,250,550 shares, compared to its average volume of 1,281,474. The company has a quick ratio of 13.49, a current ratio of 13.49 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $571.73 million, a PE ratio of -11.02 and a beta of -0.59. The firm's 50 day moving average price is $5.31 and its 200 day moving average price is $5.44. Candel Therapeutics has a 12 month low of $4.34 and a 12 month high of $7.99.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Citigroup reduced their price target on shares of Candel Therapeutics from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, March 13th. Cantor Fitzgerald assumed coverage on shares of Candel Therapeutics in a report on Monday, April 20th. They issued an "overweight" rating on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Candel Therapeutics in a report on Monday, April 20th. Canaccord Genuity Group reiterated a "buy" rating and issued a $25.00 price target on shares of Candel Therapeutics in a report on Friday, March 13th. Finally, Zacks Research downgraded shares of Candel Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, April 7th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $18.00.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, Director Paul B. Manning bought 550,458 shares of Candel Therapeutics stock in a transaction dated Monday, February 23rd. The shares were purchased at an average cost of $5.45 per share, for a total transaction of $2,999,996.10. Following the acquisition, the director directly owned 2,763,527 shares in the company, valued at approximately $15,061,222.15. This represents a 24.87% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 16.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Candel Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Candel Therapeutics during the 4th quarter valued at about $152,000. Invesco Ltd. grew its holdings in Candel Therapeutics by 29.0% during the 4th quarter. Invesco Ltd. now owns 15,039 shares of the company's stock valued at $85,000 after purchasing an additional 3,380 shares during the last quarter. XTX Topco Ltd bought a new position in Candel Therapeutics during the 4th quarter valued at about $134,000. Price T Rowe Associates Inc. MD grew its holdings in Candel Therapeutics by 31.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 25,814 shares of the company's stock valued at $146,000 after purchasing an additional 6,176 shares during the last quarter. Finally, Barclays PLC grew its holdings in Candel Therapeutics by 16.4% during the 4th quarter. Barclays PLC now owns 69,344 shares of the company's stock valued at $392,000 after purchasing an additional 9,749 shares during the last quarter. 13.93% of the stock is currently owned by institutional investors.

About Candel Therapeutics

Candel Therapeutics NASDAQ: CADL is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.